Dexcom’s Stelo Continuous Glucose Monitor Now Available OTC In US

Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.

• Source: Shutterstock

DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August for diabetics, prediabetics and healthy consumers alike, making it the first such product sold in the country that does not require a prescription.

While first to market, Dexcom is likely to face competition soon from its closest rival, Abbott , which is planning to launch its over-the-counter Lingo and Libre Rio CGM.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By 

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

People On The Move: Appointments at Hermes, Assosalute, Moberg

 
• By 

A round up of the latest European consumer health exec moves: Hermes hires management board chair; Assosalute elects directors; Moberg appoints ex-Orkla Health CEO.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

 
• By 

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.

More from Beauty

EU’s Small, Medium Beauty Industry Pushing For Clarity In Revised CPR

French SME association COSMED will push the European Commission for a “clear checklist” and criteria on how substances in the Cosmetic Products Regulation are assessed by Member States, as well as more clarity on the exemption process and timelines.

US FDA Expert Panel Paints Bleak Picture For Future Of Talc In Cosmetics

 

The US FDA’s 20 May expert panel on talc discussed science behind the potential carcinogenicity of the cosmetic, food and drug ingredient, the importance of ‘good science’ in evaluating the substance and the need to find alternatives in each industry.

J&J Plots Next Steps Following Third Failure To Resolve Talc Cases Through Bankruptcy

 
• By 

After a Texas judge denied a bankruptcy plan, Johnson & Johnson attorneys plan to focus on debunking what they see as dubious scientific claims in civil court.